HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ceriello, A. Articles by Weyer, C. Search for Related Content PubMed PubMed Citation Articles by Ceriello, A. Articles by Weyer, C. Social Bookmarking                What's this?

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes

¹ Department of Pathology and Medicine, Experimental and Clinical, University of Udine, Udine, Italy
² Amylin Pharmaceuticals, San Diego, California

Address correspondence and reprint requests to David G. Maggs, MD, Amylin Pharmaceuticals, 9360 Towne Centre Dr., San Diego, CA 92121. E-mail: dmaggs{at}amylin.com

OBJECTIVE—Oxidative stress has been shown to be increased in the postprandial period in patients with diabetes and has been implicated in the pathogenesis of micro- and macrovascular complications. The aim of this post hoc analysis was to assess the effects of pramlintide, an amylin analog shown to reduce postprandial glucose excursions in patients with diabetes, on markers of oxidative stress in the postprandial period.

RESEARCH DESIGN AND METHODS—In a randomized, single-blind, placebo-controlled, crossover study, 18 evaluable subjects with type 1 diabetes underwent two standardized breakfast meal tests and received pramlintide or placebo in addition to their preprandial insulin. The plasma concentrations of glucose and markers of oxidative stress (nitrotyrosine, oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) were measured at baseline and during the 4-h postprandial period.

RESULTS—Compared with placebo, pramlintide treatment significantly reduced postprandial excursions of glucose, nitrotyrosine, and ox-LDL and prevented a decline in TRAP (P < 0.03 for all comparisons). Correlation analyses adjusted for treatment revealed a significant association between postprandial mean incremental area under the curve from 0 to 4 h (AUC_{0–4 h}) for glucose and postprandial mean incremental AUC_{0–4 h} for each measure of oxidative stress (r = 0.75, 0.54, and –0.63 for nitrotyrosine, ox-LDL, and TRAP, respectively; P < 0.001 for all correlations).

CONCLUSIONS—These findings indicate that the postprandial glucose-lowering effect of pramlintide in type 1 diabetes is associated with a significant reduction in postprandial oxidative stress.

Abbreviations: AUC_{0–4 h}, area under the curve from 0 to 4 h • CVD, cardiovascular disease • ox-LDL, oxidized LDL • TRAP, total radical-trapping antioxidant parameter

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]

				D. Giugliano, A. Ceriello, and K. Esposito Glucose metabolism and hyperglycemia Am. J. Clinical Nutrition, January 1, 2008; 87(1): 217S - 222S. [Abstract] [Full Text] [PDF]

				B. P. Childs, N. C. Kesty, E. Klein, R. Rubin, and A. Wick Considering Pramlintide Therapy for Postprandial Blood Glucose Control Diabetes Spectr, April 1, 2007; 20(2): 108 - 114. [Abstract] [Full Text] [PDF]

				P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF]